GenomeDx Appoints Michael Rodriguez as Chief Financial Officer

SAN DIEGO, May 9, 2017 /PRNewswire/ -- GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced the appointment of Michael Rodriguez as the company's chief financial officer, effective immediately.

As chief financial officer, Mr. Rodriguez will support strategic and operational initiatives across the business and oversee accounting and finance to help drive GenomeDx's growth strategy. Mr. Rodriguez brings more than 25 years of experience to GenomeDx, including an extensive background in various senior roles within private and publicly traded diagnostics businesses, ranging from finance to operations.

Doug Dolginow, M.D., chief executive officer of GenomeDx, commented, "We are delighted to have someone of Michael's caliber join our team. His experience managing across the reimbursement landscape in diagnostics, along with a strong track record executing strategic initiatives, will be immensely valuable as GenomeDx continues its push to become the leading diagnostic company in the urologic cancer space."

Prior to joining GenomeDx, Mr. Rodriguez served as an advisor and chief financial officer of Crossover Health, a medical group delivering comprehensive primary health services to self-funded employers. Before Crossover Health, he was chief financial officer at Epic Sciences, Inc., a privately backed biotech company, where he led the securing of $40 million in equity capital and $15 million in debt financing. Earlier, Mr. Rodriguez served as chief operating officer of Clarient Diagnostic Services, a GE Healthcare molecular diagnostics and laboratory services company, where he led an organization of more than 350 people across multiple departments. Prior to his promotion to chief operating officer, he served as chief financial officer, building a best-in-class organization and guiding Clarient to profitable operations during his first year of tenure, facilitating its $587 million sale to GE Healthcare. Prior to Clarient, Mr. Rodriguez served in a variety of financial leadership roles in public and private companies spanning medical devices, healthcare information technology and business services. Mr. Rodriguez received an MBA from Stanford University and a BS in accounting from the University of Southern California.

"The genomic solutions developed by GenomeDx have the power to transform the treatment of urologic cancers, providing physicians and their patients with potentially more diagnostic information than ever before," said Mr. Rodriguez. "I am excited to be joining GenomeDx during such a dynamic time for the company and the diagnostics industry in general, and I look forward to working with this talented team to position the company for its next phase of growth."

About Decipher GRID® and Cancer Classifier Tests
GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.

Derived from GRID, GenomeDx's Decipher Prostate and Bladder Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher Post-Op is indicated for men after prostate removal surgery and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment.

More information is available at www.deciphertest.com and www.deciphergrid.com

About GenomeDx Biosciences
GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx's Decipher Biopsy, Decipher Post-Op and Decipher Bladder are commercially available urologic cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California.

Learn more at www.GenomeDx.com

SOURCE GenomeDx Biosciences

Related Links

https://www.genomedx.com